InspireMD Company Overview
•
Summary
InspireMD
Focused on preventing stroke that is estimated to cost the US healthcare system more than
$34BB annually
• The current addressable market for CGuard TM EPS is estimated to be $1BB with the
potential to further expand into the 1.6MM patient population which is diagnosed but not
treated
• Positive and consistent clinical data continues to validate the safety profile of CGuard™ EPS
with data indicating stroke prevention out to 2 years
•
•
Increasingly more presentations and live clinical cases with CGuard™ are featured at major
and regional medical conferences
Vascular surgeons treat the majority of patients with carotid artery disease: Begin a focus on
converting vascular surgeons to using CGuard™ EPS
Commercial strategy beginning to take hold as indicated by sales growth over the last year
•
Product pipeline to support continued growth in all geographies, including the United States
25View entire presentation